Johnson & Johnson Newsroom

Express News | Johnson & Johnson - Nipocalimab Shows 77% Igg Reduction in Phase 2 Study

BreakingsNov 14 23:00

Express News | Nipocalimab Demonstrates Significant Clinical Improvement in Disease Activity and Igg Reduction in Phase 2 Sjögren's Disease Study

BreakingsNov 14 23:00

Express News | Johnson & Johnson Medtech Announces Strategic Agreement With Responsive Arthroscopy to Expand Sports Soft Tissue Solutions

BreakingsNov 14 21:21

Sector Update: Health Care Stocks Edge Lower Wednesday Afternoon

MT NewswiresNov 14 02:53

Johnson & Johnson Sues US Government Over Rebate Model in Drug Discount Program

MT NewswiresNov 14 00:44

Texas Instruments and Other Overlooked Dividend Aristocrat Stocks -- Barrons.com

Barron'sNov 14 00:08

Disease activity level improvement exceeds 70%. johnson & johnson (JNJ.US) potential heavyweight monoclonal antibody receives breakthrough therapy designation.

Johnson & Johnson (JNJ.US) recently announced that the US FDA has granted breakthrough therapy designation (BTD) to its investigational antibody therapy nipocalimab targeting the neonatal Fc receptor (FcRn), for the treatment of adult patients with moderate to severe Sjogren's syndrome.

Zhitong FinanceNov 13 09:28

J&J Sues HHS Over 340B Hospital Drug-discount Program

Seeking AlphaNov 13 04:43

J&J Sues U.S. Over Hospital Drug-Discounting Program -- WSJ

WSJNov 13 04:04

3M, UnitedHealth Share Losses Lead Dow's 115-Point Drop

MarketWatchNov 12 23:28

Express News | Johnson & Johnson Medtech Receives Ide Approval for Ottava™ Robotic Surgical System

BreakingsNov 12 21:00

Johnson & Johnson (JNJ.US) nicastrin monoclonal antibody injection is planned to be included in priority review.

On November 12th, the official website of CDE announced that Johnson & Johnson (JNJ.US) nicalizumab injection is expected to be included in the priority review.

Zhitong FinanceNov 12 13:50

Johnson & Johnson Today Announces That The U.S. FDA Has Granted Nipocalimab Breakthrough Therapy Designation For The Treatment Of Adults Living With Moderate-To-Severe Sjögren's Disease, A Debilitating And Chronic Autoantibody Disease With High...

BenzingaNov 12 05:18

Express News | Nipocalimab Is the First and Only Investigational Therapy Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults Living With Moderate-to-Severe Sjögren's Disease

BreakingsNov 12 05:05

Express News | Stand up to Cancer Collaborates With Johnson & Johnson to Explore Targeted Therapies for Rare Disease Linked to Blood Cancers

BreakingsNov 11 22:00

STAND UP TO CANCER COLLABORATES WITH JOHNSON & JOHNSON TO EXPLORE TARGETED THERAPIES FOR RARE DISEASE LINKED TO BLOOD CANCERS

PR NewswireNov 11 22:00

Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Yahoo FinanceNov 11 19:01

With Johnson & Johnson (NYSE:JNJ) It Looks Like You'll Get What You Pay For

Simply Wall StNov 9 20:34

Express News | Johnson & Johnson Submits Applications in the U.S. and EU Seeking Approval of Darzalex Faspro® / Darzalex® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

BreakingsNov 8 20:00

Express News | shanghai Municipal Medical Insurance Bureau organizes centralized procurement of pharmaceuticals and high-value consumables exceeding 2 billion yuan

BreakingsNov 8 09:35